Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria- Patient level~1. Males and females; ≥ 18~2. Thermal burns caused by fire/flame, scalds or contact,~3. Patient total burns area ≥ 3% DPT and / or FT,~4. Patient total burns area should be ≤ 30% TBSA; SPT, DPT and/or FT in depth,~5. Informed consent can be obtained within 84 hours of the burn injury,~6. Patients who are willing and able to sign a written consent form.~Inclusion Criteria - Wound level~1. At least one wound (a continuous burn area) that is ≥0.5% TBSA (DPT and/or FT) (this minimal wound size should not including face, perineal or genital area.~   All planned target wounds (TWs) should meet the following criteria:~2. SPT area that cannot be demarcated from DPT and FT areas should be less than 50% of the % TBSA of the TW.~3. Wound's blisters can be removed/ unroofed, as judged by the investigator.~Exclusion Criteria- Patient level~1. Patients who are unable to follow study procedures and follow up period.~2. Modified Baux index ≥ 80,~3. Patients with burned charred fingers, 3rd degree in depth and possibly devoid of circulation,~4. Patients with abraded wound/s that cannot be treated by an enzymatic debrider application (NexoBrid) will be excluded from the study,~5. Patients with electrical or chemical burns,~6. Patients with circumferential (≥ 80% of the limb circumference) DPT and/or FT burns defined as Extremities at Risk (EAR) 2 as described in the protocol.~7. The following pre-enrollment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),~8. Patients with pre-enrolment wounds which are covered by eschar heavily saturated with iodine or by SSD pseudoeschar (e.g. pseudoeschar as a result of \> 12 hours SSD treatment),~9. Patients with pre-enrollment escharotomy.~10. Patients with diagnosed infections as described in Section 11.9 of study protocol,~11. Diagnosis of smoke inhalation injury.~12. Pregnant women (positive pregnancy test) or nursing mothers.~13. Poorly controlled diabetes mellitus (HbA1c\>11%) in patients with known diabetes as captured in the medical history.~14. BMI greater than 39.0 kg/m2 in patients with burn area up to 15% TBSA or BMI greater than 34.0 kg/m2 in patients with burn area more than 15% TBSA.~15. ASA greater than 2 (Appendix 13- ASA classification system)~16. Cardio-pulmonary disease (MI within 6 months prior to injury, severe pulmonary hypertension, severe COPD or pre-existing oxygen-dependent pulmonary diseases, severe broncho-pneumonia within 1 month prior to injury , steroid dependent asthma or uncontrolled asthma).~17. Pre-existing diseases which interfere with circulation (severe peripheral vascular disease, edema, lymphedema, regional lymph nodes, significant varicose veins),~18. Any conditions that would preclude safe participation in the study or adding further risk to the basic acute burn trauma (such as severe immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder,severe cardiovascular disorder,significant pulmonary disorder, significant liver disorder including post alcoholic abuse impaired function or neoplastic disease, blast injury)~19. Chronic systemic steroid intake,~20. History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or papain,~21. Current (within 12 months prior to screening) suicide attempt,~22. Mentally incapacitated adults who are incapable of giving legal consent~23. Enrollment in any investigational drug trial within 4 weeks prior to screening,~24. Current (within 12 months prior to screening) alcohol or drug abuse (see definition in section 1.1)~25. Prisoners and incarcerated,~26. Patients who might depend on the clinical study site or investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- NexoBrid Gel (Type: EXPERIMENTAL): NexoBrid Gel is applied to the burn wound at a dose of 2 g NexoBrid sterile powder mixed with 20g sterile Gel Vehicle per 1% of TBSA (\~ surface of an adult palm) for four hours.
- Gel Vehicle (Type: PLACEBO_COMPARATOR): Gel Vehicle is applied to the burn wound at a dose of 20 g sterile Gel per 1% of TBSA (\~ surface of an adult palm) for four hours.
- Standard of Care (SOC) (Type: ACTIVE_COMPARATOR): Subjects in the SOC group may be treated with a combination of surgical and non-surgical eschar removal procedures, according to the investigator's judgment.

Based on this trial design, predict the completion outcome and termination type (if applicable).